Lorbrena (lorlatinib)
An approved treatment for ALK-Positive Lung Cancer.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Lorlatinib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Lorlatinib
- Brand name
- Lorbrena
- Development code
- PF-06463922
- Drug class
- ALK tyrosine kinase inhibitor
- Manufacturer
- Pfizer
- How it's taken
- Oral tablets, once a day
Lorbrena (lorlatinib) is a pill taken once a day for adults with metastatic ALK-positive non-small cell lung cancer.
- That means lung cancer that has spread and whose tumor carries an ALK gene change found by an FDA-approved test[1].
- The label covers people starting their first ALK treatment and people who have already taken other ALK inhibitors[1].
- The FDA first granted accelerated approval on November 2, 2018 for people whose cancer had grown on earlier ALK inhibitors[2].
- On March 3, 2021, it expanded the approval to first treatment and converted it to full approval[3][5].
- The CROWN trial enrolled people starting treatment.
- At the time of the main analysis, the cancer grew or the person died in 28% of the lorlatinib group and 59% of the crizotinib group[1].
- Lorbrena has no boxed warning. Its warnings include effects on thinking, mood, speech and sleep[1].
We'll email you when Lorbrena's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Lorlatinib fits
Lorbrena (lorlatinib) is a once-daily ALK inhibitor pill approved for adults with metastatic ALK-positive lung cancer. It is approved whether they are starting their first ALK treatment or have already taken other ALK inhibitors[1].
- Alectinib (Alecensa), brigatinib (Alunbrig), crizotinib (Xalkori) and ceritinib (Zykadia) are also FDA approved for metastatic ALK-positive lung cancer[10][11][12][13].
- Ensartinib (Ensacove) is approved for people who have not yet taken an ALK inhibitor[14].
- Nelkarmi (neladalkib) received accelerated approval in November 2026 for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. It is for people already treated for advanced or metastatic disease with either alectinib as their only ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy[15].
- The CROWN trial compared lorlatinib with crizotinib, and the first-treatment trials in the alectinib, brigatinib and ensartinib labels also used crizotinib as the comparison[1][10][11][14].
- None of these labels describes a trial comparing lorlatinib directly with alectinib, brigatinib, ensartinib or neladalkib[1][10][11][14][15].
- Anyone curious about lorlatinib can ask their oncologist how its brain, mood and cholesterol side effects and its medicine interactions would fit their own health history and other prescriptions.
How Lorlatinib works
In ALK-positive lung cancer, a piece of the ALK gene joins another gene inside the tumor, most often one called EML4. LUNGevity explains that the fused gene makes an abnormal ALK protein that keeps telling cancer cells to grow[9]. LUNGevity also notes that this change is acquired during life rather than inherited from a parent[9]. Lorlatinib is a kinase inhibitor, a pill that blocks the ALK protein's growth signal[1].
In laboratory tests, lorlatinib blocked many changed forms of ALK that show up when cancer grows on crizotinib and other ALK inhibitors, including the resistance changes called G1202R and I1171T[1]. Lorlatinib also slowed tumors and lengthened survival in mice with ALK-driven tumors placed in the brain[1]. Besides ALK, lorlatinib blocks a related protein called ROS1 and several other kinases in laboratory tests[1].
Side effects and safety
Lorbrena has no boxed warning[1]. The label has 1 contraindication: use with strong CYP3A inducers such as rifampin. Its 8 warnings include serious liver injury with strong CYP3A inducers, brain and nervous system effects, and high cholesterol and triglycerides. The other warnings are heart rhythm block, lung inflammation, high blood pressure, high blood sugar and harm to an unborn baby[1].
Most common: Across 476 people in 2 trials, the most common side effects were swelling (56%) and nerve damage in the hands and feet called peripheral neuropathy (44%). Next most common were weight gain (31%), thinking and memory effects (28%), tiredness (27%), shortness of breath (27%), joint pain (24%), diarrhea (23%), mood effects (21%) and cough (21%)[1].
Brain and mood: Brain and nervous system effects occurred in 52% of the 476 people. They included thinking and memory changes (28%), mood changes including suicidal thoughts (21%) and sleep changes (12%). They also included speech changes (11%), hallucinations and other psychotic effects (7%) and seizures (1.9%)[1]. The median time to a first effect was 1.4 months, and 2.1% stopped Lorbrena for good because of one[1]. CROWN left out people with severe psychiatric conditions or recent suicidal thoughts or behavior[1].
Cholesterol and triglycerides: Severe rises, graded 3 or 4, occurred in 18% for total cholesterol and 19% for triglycerides. The median onset was 15 days, and 83% of people started a cholesterol- or fat-lowering medicine[1]. The label calls for blood fat tests before starting, at 1 and 2 months, and from time to time after that[1].
Heart rhythm: A slowing of the heart's electrical signal called AV block occurred in 1.9%, and 0.2% had severe AV block and got a pacemaker[1]. An ECG, a heart rhythm tracing, is done before starting and from time to time during treatment[1].
Lungs: Lung inflammation (interstitial lung disease or pneumonitis) occurred in 1.9%. Lorbrena is stopped for good if it causes lung inflammation of any degree[1].
Blood pressure and blood sugar: High blood pressure occurred in 13% and high blood sugar in 9%[1]. Blood pressure is checked after 2 weeks and at least monthly, and fasting blood sugar before starting and from time to time[1].
Liver with certain medicines: In 12 healthy volunteers who took Lorbrena with rifampin (a strong CYP3A inducer), 10 had severe liver injury. That is why the combination is not allowed[1].
Pregnancy: Lorbrena can harm an unborn baby and can make hormonal birth control stop working[1]. The label calls for women who could become pregnant to use effective nonhormonal birth control during treatment and for at least 6 months after the last dose[1]. The label calls for men with partners who could become pregnant to use effective birth control during treatment and for at least 3 months after the last dose[1]. The label also advises against breastfeeding during treatment and for 7 days after the last dose[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Lorlatinib
The label dose is 100mg by mouth once a day, at the same time each day, with or without food. Treatment continues until the cancer grows or side effects become too hard to manage[1]. Tablets come in 25mg and 100mg strengths and are swallowed whole, not chewed, crushed or split[1]. A missed dose is taken unless the next dose is due within 4 hours, and no extra dose is taken after vomiting[1].
For side effects, the doctor may pause Lorbrena or lower the dose to 75mg and then 50mg once a day. Lorbrena is stopped for good in people who cannot tolerate 50mg[1]. The label dose is 50mg a day for severe liver impairment and 75mg a day when kidney function is low, with a creatinine clearance of 15 to under 30mL/min[1].
Before starting: Cholesterol and triglycerides, an ECG, fasting blood sugar and blood pressure are checked. A pregnancy test is done for anyone who could become pregnant[1].
Other medicines: Lorbrena cannot be used with strong CYP3A inducers such as rifampin, which must be stopped for 3 of their half-lives before starting[1]. The label says to avoid moderate CYP3A inducers, strong CYP3A inhibitors and fluconazole, and gives adjusted doses if they cannot be avoided[1]. Lorlatinib itself lowers the levels of some other medicines broken down by CYP3A or carried by P-gp, including hormonal birth control[1].
Availability and cost
Only available as the brand-name product.
Help paying for Lorbrena
With private insurance, the drugmaker's copay card can lower what you pay for Lorbrena. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. People on Medicare may still qualify for the drugmaker's free medicine program. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
Pfizer Oncology Together Co-Pay Savings Program: eligible commercially insured patients may pay as little as $0 per month for Lorbrena, with a maximum benefit of $10,600 per product per calendar year. Not for anyone enrolled in Medicare, Medicaid, TRICARE, VA health care, a state prescription drug assistance program or Puerto Rico's government health plan, and not for cash-paying patients. Patients must be 18 or older. The current offer expires December 31, 2026.
For: private insurance · source - Free medicine program
Pfizer Patient Assistance Program: for eligible people with Medicare, Medicaid or other government insurance who have a financial need and cannot get help from other funding sources or Medicare Extra Help, Pfizer Oncology Together checks eligibility for free medicine. Eligible uninsured people who do not qualify for Medicaid may get Lorbrena free for up to 1 year and must reapply as needed.
For: Medicare, Medicaid, no insurance · source - Insurance and case manager help
Pfizer Oncology Together helps patients understand their insurance benefits and connects them with financial assistance resources whatever their coverage, including help searching for outside funding and Medicare Extra Help and checking Medicaid eligibility for uninsured patients. Call 1-877-744-5675, Monday to Friday, 8 AM to 8 PM ET.
For: private insurance, Medicare, Medicaid, no insurance · source
Good to know: Terms read on November 18, 2026 from the Pfizer Oncology Together co-pay terms page and the Lorbrena support page. The Pfizer Patient Assistance Program is run with the Pfizer Patient Assistance Foundation, which Pfizer describes as a separate legal entity. Pfizer does not publish the income limits for free medicine on these pages. The co-pay offer expires December 31, 2026, and needs a recheck in January 2027.
Charity funds for ALK-Positive Lung Cancer
No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.
Every program and charity fund for ALK-Positive Lung Cancer →
Clinical trial results
CROWN (NCT03052608) was a randomized, open-label Phase 3 trial in 296 adults with advanced ALK-positive non-small cell lung cancer. None had had treatment for advanced disease. It compared lorlatinib 100mg once a day with crizotinib 250mg twice a day[1][7]. People with brain metastases that were not causing symptoms could join, and 26% had them[1].
Main result: At the main analysis, the cancer grew or the person died in 41 of 149 people on lorlatinib (28%) and 86 of 147 on crizotinib (59%). The hazard ratio was 0.28[1]. Median progression-free survival, the time until the cancer grew, had not been reached on lorlatinib and was 9.3 months on crizotinib[1].
Response: Tumors shrank in 76% on lorlatinib and 58% on crizotinib, and 70% of lorlatinib responders were still responding at 12 months against 27% on crizotinib[1].
Brain: In 30 people with measurable brain metastases, brain tumors shrank in 82% of 17 on lorlatinib and 23% of 13 on crizotinib. Brain tumors disappeared on scans in 71% on lorlatinib[1].
After 5 years: A 2024 Journal of Clinical Oncology paper by the CROWN investigators reported long-term results. At 5 years, 60% of the lorlatinib group and 8% of the crizotinib group were alive without cancer growth. The trial doctors judged this in an analysis that was not planned in advance[6].
After earlier ALK inhibitors: Study B7461001 (NCT01970865) was a single-arm Phase 1/2 trial with no comparison group[1][8]. In 215 people with metastatic ALK-positive lung cancer who had already taken 1 or more ALK inhibitors, tumors shrank in 48% and responses lasted a median of 12.5 months[1]. Brain tumors shrank in 60% of 89 people with measurable brain metastases[1].
In smaller exploratory groups, tumors shrank in 39% of 119 people who had taken crizotinib and at least 1 other ALK inhibitor. They also shrank in 31% of 13 people whose only earlier ALK inhibitor was alectinib[1].
Development history
Pfizer developed lorlatinib under the code PF-06463922 and began Study B7461001 in January 2014[8]. The FDA granted accelerated approval on November 2, 2018 for metastatic ALK-positive lung cancer that had grown on earlier ALK inhibitors. This covered cancer that grew on crizotinib and at least 1 other ALK inhibitor, or on alectinib or ceritinib as the first ALK inhibitor[2][4].
CROWN began in April 2017[7]. On March 3, 2021 the FDA removed the earlier-treatment requirement. It approved Lorbrena for adults with metastatic ALK-positive lung cancer whether or not they had taken an ALK inhibitor. It also converted the accelerated approval to full approval[3][5]. The CROWN investigators published 5-year results in 2024[6]. The label was updated in January 2026 with dose changes for medicine interactions, severe liver impairment and kidney impairment[1].
Explore ALK-Positive Lung Cancer trials
Other ALK-Positive Lung Cancer treatments
Common questions about Lorlatinib
▸What is Lorlatinib (Lorbrena)?
Lorbrena (lorlatinib) is a pill taken once a day for adults with metastatic ALK-positive non-small cell lung cancer. That means lung cancer that has spread and whose tumor carries an ALK gene change found by an FDA-approved test[1]. The label covers people starting their first ALK treatment and people who have already taken other ALK inhibitors[1]. The FDA first granted accelerated approval on November 2, 2018 for people whose cancer had grown on earlier ALK inhibitors[2]. On March 3, 2021, it expanded the approval to first treatment and converted it to full approval[3][5]. The CROWN trial enrolled people starting treatment. At the time of the main analysis, the cancer grew or the person died in 28% of the lorlatinib group and 59% of the crizotinib group[1]. Lorbrena has no boxed warning. Its warnings include effects on thinking, mood, speech and sleep[1].
▸How does Lorlatinib work?
In ALK-positive lung cancer, a piece of the ALK gene joins another gene inside the tumor, most often one called EML4. LUNGevity explains that the fused gene makes an abnormal ALK protein that keeps telling cancer cells to grow[9]. LUNGevity also notes that this change is acquired during life rather than inherited from a parent[9]. Lorlatinib is a kinase inhibitor, a pill that blocks the ALK protein's growth signal[1]. In laboratory tests, lorlatinib blocked many changed forms of ALK that show up when cancer grows on crizotinib and other ALK inhibitors, including the resistance changes called G1202R and I1171T[1]. Lorlatinib also slowed tumors and lengthened survival in mice with ALK-driven tumors placed in the brain[1]. Besides ALK, lorlatinib blocks a related protein called ROS1 and several other kinases in laboratory tests[1].
▸What are the side effects of Lorlatinib?
Lorbrena has no boxed warning[1]. The label has 1 contraindication: use with strong CYP3A inducers such as rifampin. Its 8 warnings include serious liver injury with strong CYP3A inducers, brain and nervous system effects, and high cholesterol and triglycerides. The other warnings are heart rhythm block, lung inflammation, high blood pressure, high blood sugar and harm to an unborn baby[1].
Most common: Across 476 people in 2 trials, the most common side effects were swelling (56%) and nerve damage in the hands and feet called peripheral neuropathy (44%). Next most common were weight gain (31%), thinking and memory effects (28%), tiredness (27%), shortness of breath (27%), joint pain (24%), diarrhea (23%), mood effects (21%) and cough (21%)[1].
Brain and mood: Brain and nervous system effects occurred in 52% of the 476 people. They included thinking and memory changes (28%), mood changes including suicidal thoughts (21%) and sleep changes (12%). They also included speech changes (11%), hallucinations and other psychotic effects (7%) and seizures (1.9%)[1]. The median time to a first effect was 1.4 months, and 2.1% stopped Lorbrena for good because of one[1]. CROWN left out people with severe psychiatric conditions or recent suicidal thoughts or behavior[1].
Cholesterol and triglycerides: Severe rises, graded 3 or 4, occurred in 18% for total cholesterol and 19% for triglycerides. The median onset was 15 days, and 83% of people started a cholesterol- or fat-lowering medicine[1]. The label calls for blood fat tests before starting, at 1 and 2 months, and from time to time after that[1].
Heart rhythm: A slowing of the heart's electrical signal called AV block occurred in 1.9%, and 0.2% had severe AV block and got a pacemaker[1]. An ECG, a heart rhythm tracing, is done before starting and from time to time during treatment[1].
Lungs: Lung inflammation (interstitial lung disease or pneumonitis) occurred in 1.9%. Lorbrena is stopped for good if it causes lung inflammation of any degree[1].
Blood pressure and blood sugar: High blood pressure occurred in 13% and high blood sugar in 9%[1]. Blood pressure is checked after 2 weeks and at least monthly, and fasting blood sugar before starting and from time to time[1].
Liver with certain medicines: In 12 healthy volunteers who took Lorbrena with rifampin (a strong CYP3A inducer), 10 had severe liver injury. That is why the combination is not allowed[1].
Pregnancy: Lorbrena can harm an unborn baby and can make hormonal birth control stop working[1]. The label calls for women who could become pregnant to use effective nonhormonal birth control during treatment and for at least 6 months after the last dose[1]. The label calls for men with partners who could become pregnant to use effective birth control during treatment and for at least 3 months after the last dose[1]. The label also advises against breastfeeding during treatment and for 7 days after the last dose[1].
▸How is Lorlatinib taken?
The label dose is 100mg by mouth once a day, at the same time each day, with or without food. Treatment continues until the cancer grows or side effects become too hard to manage[1]. Tablets come in 25mg and 100mg strengths and are swallowed whole, not chewed, crushed or split[1]. A missed dose is taken unless the next dose is due within 4 hours, and no extra dose is taken after vomiting[1].
For side effects, the doctor may pause Lorbrena or lower the dose to 75mg and then 50mg once a day. Lorbrena is stopped for good in people who cannot tolerate 50mg[1]. The label dose is 50mg a day for severe liver impairment and 75mg a day when kidney function is low, with a creatinine clearance of 15 to under 30mL/min[1].
Before starting: Cholesterol and triglycerides, an ECG, fasting blood sugar and blood pressure are checked. A pregnancy test is done for anyone who could become pregnant[1].
Other medicines: Lorbrena cannot be used with strong CYP3A inducers such as rifampin, which must be stopped for 3 of their half-lives before starting[1]. The label says to avoid moderate CYP3A inducers, strong CYP3A inhibitors and fluconazole, and gives adjusted doses if they cannot be avoided[1]. Lorlatinib itself lowers the levels of some other medicines broken down by CYP3A or carried by P-gp, including hormonal birth control[1].
▸Is Lorlatinib FDA approved?
Yes, Lorlatinib (Lorbrena) is FDA approved (2018) for the treatment of ALK-Positive Lung Cancer.
▸Is lorlatinib a chemo?
No. Lorlatinib (Lorbrena) is a targeted pill called a kinase inhibitor, not chemotherapy.
How it works: Lorlatinib blocks the abnormal ALK protein that drives ALK-positive lung cancer.
How it's taken: The dose is 100mg by mouth once a day, with or without food.
Who it is for: Adults with metastatic non-small cell lung cancer whose tumor is ALK-positive on an FDA-approved test.
▸What are the side effects of Lorbrena?
Across 476 people in 2 trials, the most common side effects were swelling (56%), nerve damage in the hands and feet (44%) and weight gain (31%). Thinking and memory effects (28%), tiredness (27%) and shortness of breath (27%) were also among the most common.
Brain and mood: Hallucinations or effects on thinking, mood, speech or sleep occurred in 52%. Seizures occurred in 1.9% of people.
Blood fats: Severe rises, graded 3 or 4, occurred in 18% for cholesterol and 19% for triglycerides. Overall, 83% of people started a cholesterol- or fat-lowering medicine.
Other warnings: Heart rhythm block, lung inflammation, high blood pressure, high blood sugar and harm to an unborn baby. The label also warns of serious liver injury when it is taken with strong CYP3A inducers such as rifampin.
Boxed warning: None.
▸Does Lorbrena cause weight gain?
Yes, weight gain is one of the most common side effects on the Lorbrena label.
All trials: Weight gain occurred in 31% of 476 people.
CROWN: Weight gain occurred in 38% on lorlatinib and 13% on crizotinib, and was grade 3 or 4 in 17% on lorlatinib.
Swelling: Fluid swelling, a separate side effect, occurred in 56%.
Pfizer: Pfizer's Lorbrena site offers a downloadable guide on potential weight gain to discuss with the care team.
Source: Lorbrena prescribing information, DailyMed; Lorbrena support and resources, Pfizer
▸How long can you take lorlatinib?
The label says Lorbrena is taken until the cancer grows or side effects become too hard to manage, with no set end date.
CROWN at 5 years: The CROWN investigators reported that 60% of people on lorlatinib were alive without cancer growth at 5 years, against 8% on crizotinib. This 2024 analysis was not planned in advance.
Dose changes: The doctor may lower the dose to 75mg and then 50mg for side effects.
Source: Lorbrena prescribing information, DailyMed; Solomon et al., Journal of Clinical Oncology, 2024
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
- U.S. Food and Drug Administration · 2018-11-02. NDA 210868 ACCELERATED APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210868Orig1s000ltr.pdf
- U.S. Food and Drug Administration · 2021-03-03. NDA 210868/S-004 SUPPLEMENT APPROVAL/ FULFILLMENT OF POSTMARKETING REQUIREMENT. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/210868Orig1s004ltr.pdf
- Pfizer Inc. · 2018-11-02. U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC. https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_lorbrena_lorlatinib_for_previously_treated_alk_positive_metastatic_nsclc
- Pfizer Inc. · 2021-03-03. U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-expands-approval-pfizers-lorbrenar-first-line
- Journal of Clinical Oncology · 2024-10-10. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. https://pubmed.ncbi.nlm.nih.gov/38819031/
- ClinicalTrials.gov · 2026-11-18. A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC. https://clinicaltrials.gov/study/NCT03052608
- ClinicalTrials.gov · 2026-11-18. A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations. https://clinicaltrials.gov/study/NCT01970865
- LUNGevity Foundation. About ALK-positive Lung Cancer | Navigating ALK. https://alk.lungevity.org/alk/about-alk-positive-lung-cancer
- U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
- U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
- U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
- U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e
- U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e
- Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf